Ophthalmic solution

Abstract

The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient.

What is claimed is: 
     
         1 . A method for improving the duration and/or potency of the effect of an ophthalmic solution comprising 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester when administered to the eyes of a subject, comprising: adding methyl cellulose in an amount of about 0.01-10 w/v % to the ophthalmic solution. 
     
     
         2 . The method of  claim 1 , wherein the ophthalmic solution comprises 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester in an amount of about 0.001-1 w/v %. 
     
     
         3 . The method of  claim 2 , wherein the ophthalmic solution comprises 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester in an amount of about 0.12 w/v %. 
     
     
         4 . The method of  claim 1 , wherein the method improves the duration of the intraocular pressure lowering effect of the ophthalmic solution to longer than 4 hours. 
     
     
         5 . The method of  claim 1 , wherein the ophthalmic solution is administered to a patient in need thereof only once a day. 
     
     
         6 . The method of  claim 1 , further comprising a dissolving agent.